Indaptus Therapeutics, Inc.(INDP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

INDP Indaptus Therapeutics, Inc.

Pre-Mkt 12-17 05:28:43 EST

2.21

-0.10

-4.33%

High2.40	Low2.21	Vol8.34K
Open2.40	D1 Closing2.31	Amplitude8.23%
Mkt Cap3.87M	Tradable Cap1.88M	Total Shares1.75M
T/O19.17K	T/O Rate0.98%	Tradable Shares850.70K
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"INDP","market":"US","secType":"STK","nameCN":"Indaptus Therapeutics, Inc.","latestPrice":2.21,"timestamp":1765918800000,"preClose":2.31,"halted":0,"volume":8335,"delay":0,"floatShares":850699,"shares":1751163,"eps":-27.452517,"marketStatus":"Pre-Mkt","change":-0.1,"latestTime":"12-17 05:28:43 EST","open":2.4,"high":2.4,"low":2.21,"amount":19173.548,"amplitude":0.082251,"askPrice":3.25,"askSize":100,"bidPrice":2,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-27.452517,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1765981800000},"marketStatusCode":1,"adr":0,"listingDate":1438660800000,"exchange":"NASDAQ","adjPreClose":2.27,"postHourTrading":{"tag":"盘后","latestPrice":2.21,"preClose":2.21,"latestTime":"16:58 EST","volume":6,"amount":13.54,"timestamp":1765922330608},"volumeRatio":0.17828426218867238},"requestUrl":"/m/hq/s/INDP","defaultTab":"news","newsList":[{"id":"2583516290","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Indaptus Therapeutics (INDP) and Fate Therapeutics (FATE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583516290","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583516290?lang=en_us&edition=fundamental","pubTime":"2025-11-14 03:40","pubTimestamp":1763062814,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Indaptus Therapeutics (INDP – Research Report) and...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-indaptus-therapeutics-indp-and-fate-therapeutics-fate-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-indaptus-therapeutics-indp-and-fate-therapeutics-fate-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","INDP","BK4585","LU0029874061.USD","BK4139","BK4137","BK4581","HCSG","FATE","LU0128526141.USD","BK4588","LABU","XLV"],"gpt_icon":0},{"id":"2582374542","title":"Indaptus Therapeutics Q3 profit beats estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2582374542","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582374542?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:38","pubTimestamp":1762954705,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics Q3 profit beats estimatesOverviewIndaptus Q3 2025 EPS beats analyst expectations, improving from last year's lossCompany raised $2.3 mln through at-the-market facility, strengthe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL1N3WO0HI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INDP"],"gpt_icon":0},{"id":"2582374387","title":"Indaptus Therapeutics posts third quarter net loss of $2.98 per share","url":"https://stock-news.laohu8.com/highlight/detail?id=2582374387","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582374387?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:31","pubTimestamp":1762954317,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics Inc. reported research and development expenses of approximately $1.5 million for the third quarter ended September 30, 2025, an increase of $0.1 million from the same period in 2024. Net cash used in operating activities was $11.6 million for the first nine months of 2025, compared to $8.9 million for the same period in 2024. Net cash provided by financing activities for the nine months ended September 30, 2025, included a $5.7 million private placement of convertible notes and warrants in June and $2.3 million raised in September through an at-the-market facility. Loss per share was $3.0 for the third quarter of 2025, compared to $9.0 for the third quarter of 2024. As of September 30, 2025, cash and cash equivalents totaled $5.8 million. The company completed the Safety Lead-In cohort of its Phase 1 combination trial with Decoy20 and tislelizumab, dosing six evaluable participants, with three achieving stable disease at the first assessment. Indaptus expects cur","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDLbtbj4T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INDP"],"gpt_icon":0},{"id":"2582337475","title":"Rpt-Indaptus Therapeutics Q3 EPS USD -2.98","url":"https://stock-news.laohu8.com/highlight/detail?id=2582337475","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582337475?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:30","pubTimestamp":1762954202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nPLXB9930B:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INDP"],"gpt_icon":0},{"id":"2565500695","title":"Investors Await Key Jobs Data as US Futures Mixed in Friday's Premarket","url":"https://stock-news.laohu8.com/highlight/detail?id=2565500695","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565500695?lang=en_us&edition=fundamental","pubTime":"2025-09-05 20:15","pubTimestamp":1757074520,"startTime":"0","endTime":"0","summary":"US stock futures are mixed in Friday's premarket session as investors look ahead to key employment reports, as well as oil industry data coming out later in the morning.The Dow Jones Industrial Average futures were off 0.2%, S&P 500 futures were up 0.1%, and Nasdaq futures were rising 0.5%.Oil prices were moving lower, with front-month global benchmarks Brent crude and West Texas Intermediate crude declining 1% and 1.1% respectively.In equities, shares of Twin Vee Powercats  soared 53% after gaining 6.7% the previous day. Hour Loop  shares jumped 53%, piling on to a 49%  gain from Thursday. And shares of Braze  advanced 21% after it reported fiscal Q2 adjusted earnings late Thursday that beat analysts expectations.On the losing side, shares of lululemon athletica  tumbled 20% after it said overnight that it is lowering its full-year financial outlook.  American Outdoor Brands  shares shed 15% after it reported late Thursday that it swung to a loss in Q1. And shares of Indaptus Therapeu","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"9d4bdd52063afd6dc2cca6bcc6d04835","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4202","AOUT","BK4588","LU0823411888.USD","INDP","BK4613","VEEE","BRZE","BK4023","HOUR","BK4211","LULU","BK4504","BK4122","BK4539","LU1496350502.SGD","BK4585","BK4190","ISBC","BK4139","BK4220"],"gpt_icon":1},{"id":"2565077083","title":"Indaptus Therapeutics Announces Promising Updates on Decoy20 and Tislelizumab Combination Therapy in Ongoing Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2565077083","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565077083?lang=en_us&edition=fundamental","pubTime":"2025-09-05 04:02","pubTimestamp":1757016150,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics Inc. has announced updates on their ongoing INDP-D101 clinical trial involving the Decoy20 combination with the PD-1 inhibitor, tislelizumab. The trial, which is in the clinical stage, aims to explore innovative treatments for cancer and viral infections. The company has completed the monotherapy portion of the trial and initiated a cohort of seven patients for the combination therapy. Among the first three evaluable patients in the combination therapy, one patient exhibited stable disease at the first assessment, while two experienced disease progression. Additionally, a patient in the monotherapy study displayed a partial response with a reduction in liver metastases, although the disease progressed at the next imaging. Indaptus plans to continue dosing additional patients and will present further results in the coming weeks.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250904:nNDL7FVxNL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INDP"],"gpt_icon":0},{"id":"2565307799","title":"Indaptus Therapeutics Inc - Decoy20 Monotherapy Induces Partial Response in Cancer Patient","url":"https://stock-news.laohu8.com/highlight/detail?id=2565307799","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565307799?lang=en_us&edition=fundamental","pubTime":"2025-09-05 04:01","pubTimestamp":1757016060,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250904:nTUA3NPGLT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INDP","BK4139"],"gpt_icon":0},{"id":"2565307798","title":"Indaptus Therapeutics Inc - Decoy20 Combination With Pd-1 Inhibitor Shows Consistent Safety","url":"https://stock-news.laohu8.com/highlight/detail?id=2565307798","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565307798?lang=en_us&edition=fundamental","pubTime":"2025-09-05 04:01","pubTimestamp":1757016060,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250904:nTUA3NPGLT:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INDP"],"gpt_icon":0},{"id":"2559981844","title":"Indaptus Therapeutics: Files for Mixed Shelf Offering of up to $200 Mln- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2559981844","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559981844?lang=en_us&edition=fundamental","pubTime":"2025-08-14 04:19","pubTimestamp":1755116371,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nFWN3U51U3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INDP","BK4139"],"gpt_icon":0},{"id":"2559265602","title":"Rpt- Indaptus Therapeutics Inc Q2 EPS $-9.09","url":"https://stock-news.laohu8.com/highlight/detail?id=2559265602","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559265602?lang=en_us&edition=fundamental","pubTime":"2025-08-13 20:56","pubTimestamp":1755089811,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nFWN3U51SW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INDP"],"gpt_icon":0},{"id":"2559604929","title":"Indaptus Therapeutics Q2 EPS $(9.09) Beats $(9.24) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2559604929","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559604929?lang=en_us&edition=fundamental","pubTime":"2025-08-13 20:11","pubTimestamp":1755087082,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics (NASDAQ:INDP) reported quarterly losses of $(9.09) per share which beat the analyst consensus estimate of $(9.24) by 1.62 percent. This is a 30.93 percent increase over losses of $(13.16) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47087374/indaptus-therapeutics-q2-eps-9-09-beats-9-24-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","INDP"],"gpt_icon":0},{"id":"2559049246","title":"Indaptus Therapeutics Initiates Phase 1b/2 Trial Combining Decoy20 With PD-1 Inhibitor Tislelizumab for Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2559049246","media":"Reuters","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559049246?lang=en_us&edition=fundamental","pubTime":"2025-08-13 20:02","pubTimestamp":1755086520,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics, Inc., a clinical stage biotechnology company, has announced the initiation of a Phase 1b/2 combination clinical trial involving their experimental therapy, Decoy20, in conjunction with the PD-1 checkpoint inhibitor, tislelizumab. This trial aims to evaluate the efficacy of this combination in inducing solid tumor regression in patients who have not responded to existing immunotherapies. The company has reported dosing the first patient in this trial and expects to present initial data from the first cohort of patients later this year. This development marks a significant step in Indaptus' ongoing efforts to advance innovative treatments for cancer and viral infections.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advic","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nNDL5R4YYm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Indaptus Therapeutics Initiates Phase 1b/2 Trial Combining Decoy20 With PD-1 Inhibitor Tislelizumab for Cancer Treatment","news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDP","BK4139"],"gpt_icon":0},{"id":"2555069214","title":"Indaptus Therapeutics Inc. Held Special Meeting of Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2555069214","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555069214?lang=en_us&edition=fundamental","pubTime":"2025-07-30 04:16","pubTimestamp":1753820161,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics Inc. held a special meeting of shareholders on July 25, 2025. The meeting included two proposals related to a private placement. The first proposal, concerning the issuance of shares of common stock upon conversion of notes and exercise of warrants, was approved. The second proposal, regarding the issuance of shares to the Chief Executive Officer and Director upon conversion of notes and exercise of warrants, was also approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indaptus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 29, 2025, and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250729:nNDL4SWzyt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INDP"],"gpt_icon":0},{"id":"2548090110","title":"Indaptus Therapeutics Raises $3.4 Million in Additional Private Placement of Convertible Notes and Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2548090110","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548090110?lang=en_us&edition=fundamental","pubTime":"2025-07-01 20:39","pubTimestamp":1751373550,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics, Inc., a clinical stage biotechnology company focused on innovative cancer and viral infection treatments, announced an additional sale of approximately $3.4 million in convertible promissory notes and accompanying warrants. This follows a previous sale of $2.3 million, bringing the total raised to $5.7 million. The notes have a 6% annual interest rate and will mature on July 28, 2026. They will convert into common stock either 30 days post a reverse split on Nasdaq or one year from issuance, at 80% of the average closing price over the five days preceding conversion, capped at $11.20 per share. Warrants for 200% of the conversion shares will be issued post-conversion, pending stockholder approval, with a five-year term. The proceeds are intended for research, development, and general corporate purposes. Paulson Investment Company, LLC served as the exclusive placement agent for this offering.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250701:nNDLdrXm6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INDP"],"gpt_icon":0},{"id":"2546146322","title":"BRIEF-Indaptus Therapeutics Announces Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2546146322","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546146322?lang=en_us&edition=fundamental","pubTime":"2025-06-25 19:06","pubTimestamp":1750849566,"startTime":"0","endTime":"0","summary":"BRIEF-Indaptus Therapeutics Announces Reverse Stock SplitJune 25 (Reuters) - Indaptus Therapeutics Inc INDP.O:INDAPTUS THERAPEUTICS ANNOUNCES REVERSE STOCK SPLITINDAPTUS THERAPEUTICS INC - APPROVES ON","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nTUA9VCQ8H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INDP"],"gpt_icon":0},{"id":"2543435682","title":"Indaptus Therapeutics Sells $2.3 Million of Convertible Notes, Warrants; Shares Fall Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2543435682","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543435682?lang=en_us&edition=fundamental","pubTime":"2025-06-13 20:49","pubTimestamp":1749818985,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics  said Friday it sold about $2.3 million of convertible promissory notes and accompanying warrants in a private placement.A health care-focused institutional investor led the transaction in an ongoing offering, in which Indaptus is looking to raise gross proceeds of up to $5 million, the company said.Indaptus said the notes bear an annual interest rate of 6%, will mature on July 28, 2026 and will convert into common shares, while the warrants to purchase 200% of the conversion shares will be issued after the conversion of the notes and the receipt of stockholder approval.The company said it plans to use the net proceeds for research and development, including a phase 1b/2 clinical trial, and for working capital and general corporate purposes.Indaptus shares were 2.7% lower in recent premarket activity.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","INDP","BK4539","BK4139","BK4007"],"gpt_icon":0},{"id":"2542532276","title":"Indaptus Therapeutics Inc. Conducted Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2542532276","media":"Reuters","labels":["shareholding","conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542532276?lang=en_us&edition=fundamental","pubTime":"2025-06-12 04:01","pubTimestamp":1749672119,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics Inc. held its Annual Meeting on June 10, 2025. The election of Mark J. Gilbert, Hila Karah, and Robert E. Martell as Class I directors was approved. The ratification of Haskell & White LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was approved. An amendment to the company's Amended and Restated Certificate of Incorporation to effect a reverse stock split within a specified range was also approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indaptus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commissio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250611:nNDL27zX21:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDP","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.indaptusrx.com","stockEarnings":[{"period":"1week","weight":-0.15},{"period":"1month","weight":-0.1195},{"period":"3month","weight":-0.0675},{"period":"6month","weight":-0.7601},{"period":"1year","weight":-0.9178},{"period":"ytd","weight":-0.9063}],"compareEarnings":[{"period":"1week","weight":-0.0061},{"period":"1month","weight":0.0103},{"period":"3month","weight":0.0299},{"period":"6month","weight":0.1363},{"period":"1year","weight":0.1188},{"period":"ytd","weight":0.1583}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.016627},{"month":2,"riseRate":0.4,"avgChangeRate":0.005265},{"month":3,"riseRate":0.5,"avgChangeRate":-0.057576},{"month":4,"riseRate":0.3,"avgChangeRate":-0.031116},{"month":5,"riseRate":0.4,"avgChangeRate":-0.05581},{"month":6,"riseRate":0.5,"avgChangeRate":-0.001521},{"month":7,"riseRate":0.4,"avgChangeRate":-0.067711},{"month":8,"riseRate":0.4,"avgChangeRate":0.036746},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.055501},{"month":10,"riseRate":0.272727,"avgChangeRate":-0.090558},{"month":11,"riseRate":0.272727,"avgChangeRate":-0.057102},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.055134}],"exchange":"NASDAQ","name":"Indaptus Therapeutics, Inc.","nameEN":"Indaptus Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Indaptus Therapeutics, Inc.(INDP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Indaptus Therapeutics, Inc.(INDP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Indaptus Therapeutics, Inc.,INDP,Indaptus Therapeutics, Inc.股票,Indaptus Therapeutics, Inc.股票老虎,Indaptus Therapeutics, Inc.股票老虎国际,Indaptus Therapeutics, Inc.行情,Indaptus Therapeutics, Inc.股票行情,Indaptus Therapeutics, Inc.股价,Indaptus Therapeutics, Inc.股市,Indaptus Therapeutics, Inc.股票价格,Indaptus Therapeutics, Inc.股票交易,Indaptus Therapeutics, Inc.股票购买,Indaptus Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Indaptus Therapeutics, Inc.(INDP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Indaptus Therapeutics, Inc.(INDP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction